ArticleESMO open2022

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.

A Lasagna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.